PLX R&D to Revenue
Protalix Biotherapeutics Inc · R&D to Revenue
PLX R&D to Revenue
Latest reported36.13%period ending
PLX FY R&D/Revenue (0.00% → 36.13%)
Latest values, visible window
High-resolution chart · PNG
PLX r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 36.1254% | |
| 24.2888% | |
| 26.0986% | |
| 61.6084% | |
| 77.5332% | |
| 60.6808% | |
| 81.5753% | |
| 97.3423% | |
| 136.7967% | |
| 330.6012% | |
| 458.868% | |
| 180.4222% | |
| 253.8435% | |
| 83.3401% | |
| 370.1765% | |
| 266.3732% | |
| 5,576.8041% | |
| 0% | |
| 0% | |
| 3,497.3333% | |
| 2,349.3333% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |